资料显示，深圳迈瑞生物医疗电子股份有限公司位于广东省深圳市南山区高新技术产业园区科技南十二 路迈瑞大厦1-4层，成立日期1999年1月25日，上市日期2018年10月16日，公司主营业务涉及医疗器械的 研发、制造、营销及服务。主营业务收入构成为：体外诊断类产品38.37%，生命信息与支持类产品 32.73%，医学影像类产品19.78%，电生理与血管介入类产品7.25%，其他产品1.56%，其他(补 充)0.31%。 迈瑞医疗所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：血氧仪、智慧医疗、体 外诊断、医疗器械、融资融券等。 10月10日，迈瑞医疗盘中下跌2.00%，截至10:59，报243.27元/股，成交9.22亿元，换手率0.31%，总市 值2949.51亿元。 资金流向方面，主力资金净流入2472.10万元，特大单买入1.11亿元，占比12.00%，卖出1.02亿元，占比 11.11%；大单买入2.46亿元，占比26.69%，卖出2.30亿元，占比24.90%。 迈瑞医疗今年以来股价跌3.36%，近5个交易日跌0.71%，近20日涨4.77%，近60日涨11.93%。 分红方面，迈瑞医疗 ...

Core Viewpoint - Mindray Medical experienced a stock price increase of 2.03% on September 30, reaching 243.86 CNY per share, with a total market capitalization of 295.67 billion CNY [1] Financial Performance - For the first half of 2025, Mindray Medical reported a revenue of 16.743 billion CNY, a year-on-year decrease of 18.45%, and a net profit attributable to shareholders of 5.069 billion CNY, down 32.96% year-on-year [2] - Since its A-share listing, Mindray Medical has distributed a total of 33.699 billion CNY in dividends, with 23.388 billion CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders for Mindray Medical was 91,600, a decrease of 0.68% from the previous period, with an average of 13,241 circulating shares per person, an increase of 0.69% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, holding 131 million shares, a decrease of 3.0252 million shares from the previous period [3]

Core Points - The stock price of Mindray Medical has decreased by 4.62% year-to-date, with a recent increase of 2.17% over the last five trading days [2] - As of June 30, 2025, Mindray Medical reported a revenue of 16.743 billion yuan, a year-on-year decrease of 18.45%, and a net profit of 5.069 billion yuan, down 32.96% year-on-year [2] - The company has distributed a total of 33.699 billion yuan in dividends since its A-share listing, with 23.388 billion yuan distributed in the last three years [3] Company Overview - Mindray Medical, established on January 25, 1999, and listed on October 16, 2018, is located in Shenzhen, Guangdong Province, and specializes in the research, manufacturing, marketing, and service of medical devices [2] - The company's main business revenue composition includes: in vitro diagnostic products (38.37%), life information and support products (32.73%), medical imaging products (19.78%), electrophysiology and vascular intervention products (7.25%), and other products (1.56%) [2] Shareholder Information - As of June 30, 2025, the number of shareholders for Mindray Medical was 91,600, a decrease of 0.68% from the previous period [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 131 million shares, a decrease of 3.0252 million shares from the previous period [3]

Core Insights - The stock price of Mindray Medical increased by 2.01% on September 25, reaching 238.60 CNY per share, with a trading volume of 1.29 billion CNY and a market capitalization of 289.29 billion CNY [1] - Year-to-date, the stock has decreased by 5.21%, with a slight increase of 0.34% over the last five trading days [1] Financial Performance - For the first half of 2025, Mindray Medical reported a revenue of 16.743 billion CNY, a year-on-year decrease of 18.45%, and a net profit attributable to shareholders of 5.069 billion CNY, down 32.96% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 33.699 billion CNY, with 23.388 billion CNY distributed over the last three years [3] Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 0.68% to 91,600, while the average number of tradable shares per person increased by 0.69% to 13,241 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, holding 131 million shares, a decrease of 3.0252 million shares from the previous period [3]

Company Overview - Shenzhen Mindray Bio-Medical Electronics Co., Ltd. was established on January 25, 1999, and listed on October 16, 2018. The company is located in the High-tech Industrial Park, Nanshan District, Shenzhen, Guangdong Province. Its main business involves the research, manufacturing, marketing, and service of medical devices [1]. Financial Performance - As of June 30, 2025, Mindray Medical reported a revenue of 16.743 billion yuan, a year-on-year decrease of 18.45%. The net profit attributable to shareholders was 5.069 billion yuan, down 32.96% year-on-year [2]. - Cumulative cash dividends since the A-share listing amount to 33.699 billion yuan, with 23.388 billion yuan distributed in the last three years [3]. Stock Market Activity - On September 4, 2023, Mindray Medical's stock price fell by 2.05%, closing at 233.92 yuan per share, with a trading volume of 1.417 billion yuan and a turnover rate of 0.49%. The total market capitalization was 283.614 billion yuan [1]. - Year-to-date, the stock price has decreased by 7.55%, with a 5-day decline of 5.33%, a 20-day increase of 1.36%, and a 60-day decrease of 1.13% [1]. Shareholder Structure - As of June 30, 2025, the number of shareholders was 91,600, a decrease of 0.68% from the previous period. The average number of circulating shares per person increased by 0.69% to 13,241 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, holding 131 million shares (a decrease of 3.0252 million shares), and E Fund's various ETFs, with mixed changes in holdings [3]. Business Segmentation - The revenue composition of Mindray Medical includes: in vitro diagnostic products (38.37%), life information and support products (32.73%), medical imaging products (19.78%), electrophysiology and vascular intervention products (7.25%), and other products (1.56%) [1].

8月7日，迈瑞医疗今日收盘230.79元，上涨1.09%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到25.12倍，总市值2798.19亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入82.37亿元，同比-12.12%；净利润26.29亿元，同 比-16.81%，销售毛利率62.53%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13迈瑞医疗25.1223.987.252798.19亿行业平均 54.7951.294.80116.92亿行业中值37.8638.002.7755.22亿1九安医疗11.1511.280.88188.19亿2英科医疗 15.9217.161.42251.53亿3新华医疗16.1314.951.32103.38亿4振德医疗16.1915.261.0358.78亿5山东药玻 16.2416.291.87153.63亿6奥美医疗16.7216.391.7260.41亿7康德莱17.6917.711.4738.13亿8维力医疗 17.7518.972.2341.62亿9九强生物17.8316.582.1888.30亿10奥泰生物18.5619.571 ...

8月1日，迈瑞医疗今日收盘227.23元，下跌1.72%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到24.74倍，总市值2755.03亿元。 来源：金融界 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均53.65倍，行业中值37.22倍，迈瑞医疗排 名第51位。 资金流向方面，8月1日，迈瑞医疗主力资金净流出6780.86万元，近5日总体呈流出状态，5日共流出 17238.29万元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13迈瑞医疗24.7423.617.142755.03亿行业平均 53.6550.024.68114.74亿行业中值37.2237.112.6755.30亿1九安医疗11.0111.130.87185.78亿2英科医疗 15.4516.651.37244.06亿3新华医疗15.7214.571.28100.77亿4山东药玻16.0216.071.84151.57亿5振德医疗 16.2915.351.0459.13亿6奥美医疗16.4116.081.6959.27亿7九强生物17.4416.212.1486.36亿8康德莱 17.6117.631.46 ...

Group 1 - The core viewpoint of the articles highlights that Mindray Medical's stock price closed at 237.96 yuan, with a PE ratio of 25.91, marking a new low in 84 days, and a total market capitalization of 288.51 billion yuan [1] - The average PE ratio for the medical device industry is 55.15, with a median of 37.48, positioning Mindray Medical at the 51st rank within the industry [1] - As of March 31, 2025, the number of shareholders for Mindray Medical increased to 92,191, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Mindray Medical's main business includes the research, manufacturing, marketing, and service of medical devices, with key products in life information and support, in vitro diagnostics, medical imaging, electrophysiology, and vascular intervention [1] - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 8.237 billion yuan, a year-on-year decrease of 12.12%, and a net profit of 2.629 billion yuan, down 16.81%, with a gross profit margin of 62.53% [1] - The PE ratios of other companies in the medical device industry range from 11.07 to 20.21, with Mindray Medical's PE ratio being significantly lower than the industry average [2]

Core Viewpoint - Mindray Medical is planning a secondary listing in Hong Kong to raise up to $1 billion, marking a significant step in its global expansion and reflecting the changing role of domestic high-end medical device companies on the global stage [1] Group 1: Business Structure and Financial Performance - Mindray's business framework consists of three main pillars: Life Information and Support, In Vitro Diagnostics, and Medical Imaging, which together form a robust revenue base [2] - In 2024, the company reported total revenue of 36.73 billion RMB, with a net profit of approximately 11.7 billion RMB and R&D investment exceeding 4 billion RMB, maintaining a high ratio of about 11% of revenue [2] Group 2: Technological Integration and AI - Mindray has developed the "Three Rui" ecosystem, enhancing system integration capabilities and supporting hospitals' shift from single-device procurement to comprehensive solutions [5] - The launch of the "Qiyuan" critical care AI model in 2024, achieving over 95% accuracy, signifies a major milestone in the application of domestic medical AI products in clinical settings [10] Group 3: Globalization Strategy - Mindray's international strategy has evolved from exporting low-cost devices to penetrating high-end markets, with international revenue reaching 16.4 billion RMB in 2024, a 21.3% increase year-on-year [13] - The company has established localized production projects in 13 countries, transitioning from an "exporter" to a "global medical solution provider" [14] Group 4: New Growth Areas - Mindray is actively expanding into minimally invasive surgery and high-value consumables, acquiring a 24.61% stake in Huatai Medical for 6.65 billion RMB to enter the cardiovascular intervention market [15] - The minimally invasive surgery business has seen over 90% growth, with a focus on creating a "closed-loop ecosystem" through bundled sales of equipment, consumables, and algorithms [16] Group 5: Market Challenges and Competitive Landscape - The industry faces challenges from centralized procurement policies, which have significantly impacted pricing and profit margins, necessitating a balance between innovation and efficiency [17] - Domestic competitors are rapidly emerging, requiring Mindray to leverage R&D and system integration capabilities to maintain a competitive edge [17] Group 6: Strategic Timing for Hong Kong Listing - The timing of Mindray's secondary listing is influenced by external market conditions and internal business structure upgrades, aiming to enhance its global strategy [18] Group 7: Implications for the Industry - Mindray's secondary listing serves as a benchmark for the Chinese medical device industry, signaling a shift from "import substitution" to "exporting standards" [19] - The company's journey towards becoming a global player will be closely watched, with potential for other domestic firms to follow suit in various specialized fields [19][20]

Company Overview - Shenzhen Mindray Bio-Medical Electronics Co., Ltd. specializes in the research, manufacturing, marketing, and service of medical devices [1] - The main products include life information and support products, in vitro diagnostic products, medical imaging products, electrophysiology and vascular intervention products, and other products [1] Financial Performance - As of the latest quarterly report for Q1 2025, the company achieved operating revenue of 8.237 billion yuan, a year-on-year decrease of 12.12% [1] - The net profit for the same period was 2.629 billion yuan, reflecting a year-on-year decline of 16.81% [1] - The gross profit margin stands at 62.53% [1] Market Position - The closing stock price on July 4 was 223.8 yuan, with a rise of 1.63% [1] - The rolling price-to-earnings (PE) ratio is 24.36, while the industry average PE ratio is 51.05 [1][2] - The total market capitalization is 271.344 billion yuan [1] Capital Flow - On July 4, the net outflow of main funds was 10.2821 million yuan, with a total outflow of 148.5139 million yuan over the past five days [1]